CDH11 and metastatic malignant neoplasm in the lymph nodes: The positive expression rates of the CDH11 protein in the OSCC patients with lymph node metastasis were 62.16% (N1) and 60.87% (N2) (23/37; 14/23) respectively, which were obviously higher than those in the OSCC patients without lymph node metastasis (N0) (26.09%; 6/23) (p < 0.05) (Table 1).